When to Stop

• Hypersensitivity reactions — rare urticaria, contact dermatitis. Cross-reactivity with other Passifloraceae or composites possible.
• Hepatotoxicity — LiverTox Likelihood E (unlikely cause of clinically apparent liver injury). The NIH LiverTox database reviewed all available case literature and concluded passionflower itself has not been convincingly linked to clinical liver injury despite widespread use. Rare case reports exist but are confounded — almost all involve multi-herb products (kava + passionflower + others) where another herb is the more likely culprit, or involve pyrrolizidine-alkaloid (PA)-contaminated products sourced from disreputable suppliers using related Passiflora species or contaminated raw material. PA contamination is a known herbal-supplement issue (comfrey, borage, coltsfoot are the classical culprits); for Passiflora specifically, using a reputable standardized supplier with COA testing essentially eliminates this concern.
• QT prolongation, hypotension, vasculitis — isolated case reports at high doses; not a typical concern at standard dosing.
• Pregnancy uterotonic — animal studies show uterine contraction activity; theoretical abortifacient risk. Hard contraindication in pregnancy.
• First week of regular use: assess for paradoxical reactions (rare jitteriness, agitation reported in dopamine.club community data — 4 reports; mechanism unclear, possibly batch-related β-carboline content). Discontinue if observed.
• First dose at higher tier (700-1000 mg): ensure timing allows full ~4 hr action curve before driving or operating heavy machinery. At 500 mg or less, no functional impairment in surgical-trial populations.
• Pre-surgical period: discontinue 1-2 weeks before elective surgery — additive sedation with anesthetics theoretically possible (most clinical anesthesia teams recommend pausing all herbal anxiolytics pre-op despite Passiflora's specific use as pre-op anxiolytic in some protocols; defer to your anesthesiologist).